Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | SLC6A12 | P48065 | 4/20 | 0.58 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.58 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.58 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.58 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.58 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920364 | 0.81 | GABRA5 (0.52) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2919171 | 0.80 | BRD4 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2914571 | 0.80 | SLC6A1 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL30299155 | 0.78 | SLC6A11 (0.75) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2918774 | 0.78 | SLC6A11 (0.75) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2910527 | 0.77 | SLC6A1 (0.34) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2911526 | 0.76 | — | — | |
| SCHEMBL24478321 | 0.74 | — | — | |
| SCHEMBL2450833 | 0.74 | — | — | |
| SCHEMBL374930 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | SLC6A1 1251/4885GABRA5 2263/4885GABRB2 2357/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | SLC6A1 1341/4885GABRA5 1691/4885GABRB2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.